The 9 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 22.50, with a high estimate of 27.00 and a low estimate of 13.00. The median estimate represents a +35.38% increase from the last price of 16.62.
The current consensus among 10 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since August, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.08
Reporting Date Oct 31
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.